Search
Inhibikase Therapeutics Inc
IKTAdd to Watchlist
2.100USD
-0.050-2.33%
Close 09-24 16:00（ET）
329.76MMarket Cap
LossP/E TTM
Inhibikase Therapeutics Inc (IKT) Stock Price Target & Forecast
Analyst Rating
Based on 9 analysts giving stock ratings to Inhibikase Therapeutics Inc in the past month.
Buy
4 Strong Buy
5 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
6.000USD+179.07%
IKT Analyst Recommendation Trends
In the current month, IKT has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IKT average Analyst price target in the last month is 6.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
3
2
2
3
2
2
5
5
5
5
5
5
5
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
9
8
7
7
8
7
7
IKT Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, IKT EPS is projected to reach -0.112 in FY2026Q3, following reported EPS of -0.112 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.10
-0.11
-0.11
-0.11
-0.12
Actual
-0.10
-0.10
-0.11
--
--
Surprise
+0.14%
+12.24%
-4.88%
--
--
FAQs
What is Inhibikase Therapeutics Inc's price target?
Analysts forecast that Inhibikase Therapeutics Inc's price target is USD 6.00, with the highest forecast at USD 8.00 and the lowest forecast at USD 3.00.
How have Inhibikase Therapeutics IncIKT's recent earnings per share performed?
The market expectation was USD -0.11, while Inhibikase Therapeutics IncIKT's earnings per share (EPS) for the previous quarter was USD -0.10. EPS for the next quarter is expected at USD -0.11.
What is the analyst rating for Inhibikase Therapeutics Inc?
Based on the ratings of Inhibikase Therapeutics Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.